Latest News about Gene Therapy
Recent news which mentions Gene Therapy
YouthBio Therapeutics Announces Significant Results from Joint Study with Dr. Ocampo Demonstrating Amelioration of Age-Related Cognitive Decline
August 06, 2024
From PRLog
From Benzinga
From Benzinga
From Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
April 02, 2024
From Benzinga
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
June 08, 2023
From Benzinga
FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder
May 15, 2023
Tickers
SRPT
From Benzinga
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
April 13, 2023
From Benzinga
6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative'
April 07, 2023
From Benzinga
Tesla, Meta, Thermogenesis, Adobe, UiPath: Why These 5 Stocks Are Drawing Investors' Attention Today
March 15, 2023
From Benzinga
Regenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease Severity
November 03, 2022
Tickers
RGNX
From Benzinga
From PRUnderground
This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says
August 23, 2022
Tickers
OCGN
From Benzinga
Bluebird's Gene Therapy Scores US Approval For Genetic Blood Disorder, Probably The Most Expensive
August 17, 2022
Tickers
BLUE
From Benzinga
Homology Medicines Announces Preclinical Gene Therapy Candidate For Genetic Storage Disorder
August 12, 2022
Tickers
FIXX
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
June 13, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.